Ars Operation Drug Patent Portfolio

Ars Operation owns 1 orange book drug protected by 8 US patents Given below is the list of Ars Operation's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10682414 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
Active
US11191838 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
Active
US11717571 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
Active
US11744895 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
Active
US11918655 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
Active
US12324838 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
Active
US10576156 Compositions for drug administration 06 Feb, 2038
Active
US11173209 Compositions for drug administration 06 Feb, 2038
Active


Given below is the list of recent legal activities going on the following drug patents of Ars Operation.

Activity Date Patent Number
Patent litigations
Recordation of Patent Grant Mailed 17 Jun, 2025 US12324838
Mail Patent eGrant Notification 10 Jun, 2025 US12324838
Email Notification 10 Jun, 2025 US12324838
Recordation of Patent eGrant 10 Jun, 2025 US12324838
Patent eGrant Notification 10 Jun, 2025 US12324838
Patent Issue Date Used in PTA Calculation 10 Jun, 2025 US12324838
Payment of Maintenance Fee, 4th Year, Large Entity 09 Jun, 2025 US11191838
Email Notification 31 May, 2025 US12324838
Issue Notification Mailed 28 May, 2025 US12324838
Application Is Considered Ready for Issue 09 May, 2025 US12324838
Dispatch to FDC 09 May, 2025 US12324838
Issue Fee Payment Received 07 May, 2025 US12324838
Issue Fee Payment Verified 07 May, 2025 US12324838
Payment of Maintenance Fee, 4th Year, Large Entity 24 Apr, 2025 US11173209
Review Certificate Mailed 08 Apr, 2025 US10682414


Ars Operation's Drug Patent Litigations

Ars Operation's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 12, 2021, against patent number US10682414. The petitioner Amphastar Pharmaceuticals, Inc., challenged the validity of this patent, with Aegis Therapeutics, LLC et al. as the respondent. Click below to track the latest information on how companies are challenging Ars Operation's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10682414 August, 2021 Final Written Decision
(09 Feb, 2023)
Aegis Therapeutics, LLC et al. Amphastar Pharmaceuticals, Inc.


Ars Operation's Family Patents


Family Patents



Recent FDA approvals and tentative approvals for Ars Operation

This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.

Innovator drugs

Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.

Drug Name Submission class (FDA) Submission Category Submission Date
Neffy SUPPL-2
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Efficacy 25 Feb, 2026

Ars Operation Drug List

Given below is the complete list of Ars Operation's drugs and the patents protecting them.


1. Neffy

Neffy is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10682414 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
(12 years from now)
Active
US11191838 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
(12 years from now)
Active
US11717571 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
(12 years from now)
Active
US11744895 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
(12 years from now)
Active
US11918655 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
(12 years from now)
Active
US12324838 Intranasal epinephrine formulations and methods for the treatment of disease 06 Feb, 2039
(12 years from now)
Active
US10576156 Compositions for drug administration 06 Feb, 2038
(11 years from now)
Active
US11173209 Compositions for drug administration 06 Feb, 2038
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neffy's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List